It was therefore also explored as a promising Cav1.3 inhibitor in a clinical trial in patients with primary aldosteronism [8], but its proposed selectivity for Cav1.3 versus Cav1.2 has never been investigated. Here, CACNA1D is linked to primary aldosteronism.